{"id":5829,"date":"2022-04-29T14:26:18","date_gmt":"2022-04-29T21:26:18","guid":{"rendered":"https:\/\/metastatictrialtalk.org\/?p=5829"},"modified":"2022-04-29T14:26:18","modified_gmt":"2022-04-29T21:26:18","slug":"tnbc-targeted-therapy","status":"publish","type":"post","link":"https:\/\/breastcancertrialtalk.org\/?p=5829","title":{"rendered":"Triple-Negative Metastatic Breast Cancer: Beyond ER, PR, and HER2"},"content":{"rendered":"<p><span style=\"font-weight: 400; font-size: 12pt; color: #333333;\"><span style=\"font-size: 12pt; color: #333333;\"><span style=\"font-weight: 400;\"><img loading=\"lazy\" decoding=\"async\" class=\"alignleft wp-image-5831 size-medium\" src=\"https:\/\/breastcancertrialtalk.org\/wp-content\/uploads\/AdobeStock_124042018-300x200.jpeg\" alt=\"\" width=\"300\" height=\"200\" \/><\/span><\/span><\/span><span style=\"font-size: 12pt; color: #333333;\"><span style=\"font-weight: 400;\">Triple-negative breast cancer is defined as being negative for the estrogen receptor, progesterone receptor, and HER2 biomarkers. Because of this, targeted therapies for<\/span> <span style=\"font-weight: 400;\">these biomarkers do not work for triple-negative MBC. As a result, triple-negative MBC is commonly only treated with chemotherapy. However, researchers are beginning to understand that triple-negative MBC expresses other biomarkers that can be treated with targeted therapy.<\/span><\/span><\/p>\n<p><span style=\"font-weight: 400; font-size: 12pt; color: #333333;\">Read more about targeted therapy, and learn about potential targeted therapies for triple-negative MBC.<\/span><\/p>\n<h6><span style=\"font-size: 12pt; color: #333333;\"><b>Targeted Therapy and Triple-Negative MBC<\/b><\/span><\/h6>\n<ul>\n<li><span style=\"font-size: 12pt; color: #333333;\"><span style=\"font-weight: 400;\">ASCO:<\/span><span style=\"color: #339966;\"><a style=\"color: #339966;\" href=\"https:\/\/www.cancer.net\/navigating-cancer-care\/how-cancer-treated\/personalized-and-targeted-therapies\/understanding-targeted-therapy\" target=\"_blank\" rel=\"noopener\"> <span style=\"font-weight: 400;\">Understanding Targeted Therapy<\/span><\/a><\/span><\/span><\/li>\n<li><span style=\"font-size: 12pt; color: #333333;\"><span style=\"font-weight: 400;\">Cancer Connect:<\/span><span style=\"color: #339966;\"><a style=\"color: #339966;\" href=\"https:\/\/news.cancerconnect.com\/triple-negative-breast-cancer\/update-on-strategies-to-improve-treatment-for-triple-negative-breast-cancer\" target=\"_blank\" rel=\"noopener\"> <span style=\"font-weight: 400;\">Update on Strategies to Improve Treatment for Triple-Negative Breast Cancer<\/span><\/a><\/span><\/span><\/li>\n<\/ul>\n<h6><span style=\"font-size: 12pt; color: #333333;\"><b>Target: PD-L1<\/b><\/span><\/h6>\n<ul>\n<li><span style=\"font-size: 12pt; color: #333333;\"><span style=\"font-weight: 400;\">Metastatic Trial Talk: <\/span><span style=\"color: #339966;\"><a style=\"color: #339966;\" href=\"https:\/\/breastcancertrialtalk.org\/research-news\/immune-checkpoint-inhibitor\/\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\">Immune Checkpoint Inhibitors<\/span><\/a><\/span><\/span><\/li>\n<li><span style=\"font-size: 12pt; color: #333333;\"><span style=\"font-weight: 400;\">Breastcancer.org:<\/span><span style=\"color: #339966;\"><a style=\"color: #339966;\" href=\"https:\/\/www.breastcancer.org\/treatment\/immunotherapy\/keytruda\" target=\"_blank\" rel=\"noopener\"> <span style=\"font-weight: 400;\">Pembrolizumab (Keytruda\u00ae)<\/span><\/a><\/span><\/span><\/li>\n<\/ul>\n<h6><span style=\"font-size: 12pt; color: #333333;\"><b>Target: Trop2<\/b><\/span><\/h6>\n<ul>\n<li><span style=\"font-size: 12pt; color: #333333;\"><span style=\"font-weight: 400;\">National Cancer Institute:<\/span><span style=\"color: #339966;\"><a style=\"color: #339966;\" href=\"https:\/\/www.cancer.gov\/news-events\/cancer-currents-blog\/2020\/fda-sacituzumab-govitecan-triple-negative-breast-cancer\" target=\"_blank\" rel=\"noopener\"> <span style=\"font-weight: 400;\">Sacituzumab Govitecan for Metastatic Triple-Negative Breast Cancer<\/span><\/a><\/span><\/span><\/li>\n<li><span style=\"font-size: 12pt; color: #333333;\"><span style=\"font-weight: 400;\">Breastcancer.org:<\/span><span style=\"color: #339966;\"><a style=\"color: #339966;\" href=\"https:\/\/www.breastcancer.org\/treatment\/targeted-therapy\/trodelvy\" target=\"_blank\" rel=\"noopener\"> <span style=\"font-weight: 400;\">Sacituzumab Govitecan-hziy (Trodelvy\u00ae)<\/span><\/a><\/span><\/span><\/li>\n<\/ul>\n<h6><span style=\"font-size: 12pt; color: #333333;\"><b>Target: Androgen Receptors<\/b><\/span><\/h6>\n<ul>\n<li><span style=\"font-size: 12pt; color: #333333;\"><span style=\"font-weight: 400;\">Journal Article:<\/span><span style=\"color: #339966;\"><a style=\"color: #339966;\" href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/29373071\/\" target=\"_blank\" rel=\"noopener\"> <span style=\"font-weight: 400;\">Enzalutamide for the Treatment of Androgen Receptor-Expressing Triple-Negative Breast Cancer<\/span><\/a><\/span><\/span><\/li>\n<li><span style=\"font-size: 12pt; color: #333333;\"><span style=\"font-weight: 400;\">Breast Cancer Research Foundation:<\/span><span style=\"color: #339966;\"><a style=\"color: #339966;\" href=\"https:\/\/www.bcrf.org\/blog\/new-study-identifies-possible-dual-treatment-triple-negative-breast-cancer\/\" target=\"_blank\" rel=\"noopener\"> <span style=\"font-weight: 400;\">Possible Dual Treatment for Triple-Negative Breast Cancer<\/span><\/a><\/span><\/span><\/li>\n<li><span style=\"font-size: 12pt; color: #333333;\"><span style=\"font-weight: 400;\">Cancer Connect:<\/span><span style=\"color: #339966;\"><a style=\"color: #339966;\" href=\"https:\/\/news.cancerconnect.com\/breast-cancer\/androgen-receptor-may-contribute-to-some-cases-of-triple-negative-breast-cancer\" target=\"_blank\" rel=\"noopener\"> <span style=\"font-weight: 400;\">Androgen Receptor May Contribute to Some Cases of Triple-Negative Breast Cancer<\/span><\/a><\/span><\/span><\/li>\n<\/ul>\n<h6><span style=\"font-size: 12pt; color: #333333;\"><b>Target: AKT<\/b><\/span><\/h6>\n<ul>\n<li><span style=\"font-size: 12pt; color: #333333;\"><span style=\"font-weight: 400;\">Journal Article:<\/span><span style=\"color: #339966;\"><a style=\"color: #339966;\" href=\"https:\/\/www.nature.com\/articles\/s41571-019-0322-1\" target=\"_blank\" rel=\"noopener\"> <span style=\"font-weight: 400;\">AKT Inhibition Improves Overall Survival in Triple-Negative Breast Cancer<\/span><\/a><\/span><\/span><\/li>\n<li><span style=\"font-size: 12pt; color: #333333;\"><span style=\"font-weight: 400;\">ASCO:<\/span><a style=\"color: #333333;\" href=\"https:\/\/ascopost.com\/issues\/january-25-2021\/ipatasertib-plus-paclitaxel-falters-in-advanced-triple-negative-breast-cancer-phase-iii-trial\/\" target=\"_blank\" rel=\"noopener\"> <span style=\"font-weight: 400;\"><span style=\"color: #339966;\">AKT Targeted Therapy Needs Further Research for TNBC<\/span><\/span><\/a><\/span><\/li>\n<\/ul>\n<h6><span style=\"font-size: 12pt; color: #333333;\"><b>Metastatic Trial Search: Trials for Triple-Negative MBC Targets<\/b><\/span><\/h6>\n<ul>\n<li><span style=\"font-size: 12pt; color: #339966;\"><a style=\"color: #339966;\" href=\"https:\/\/www.breastcancertrials.org\/bct_nation\/mts\/mtsResult.seam?zip=94107&amp;gender=na&amp;er=negative&amp;pr=negative&amp;her2=negative&amp;radiusMiles=-1\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\">Triple-Negative MBC Trials<\/span><\/a><\/span><\/li>\n<li><span style=\"font-size: 12pt; color: #333333;\"><a style=\"color: #333333;\" href=\"https:\/\/www.breastcancertrials.org\/bct_nation\/mts\/mtsResult.seam?zip=94107&amp;gender=na&amp;searchTerm1=pd-1&amp;searchTerm2=pd-l1&amp;andor=or&amp;radiusMiles=-1\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\"><span style=\"color: #339966;\">PD-1\/PD-L1 Trials<\/span><\/span><\/a><\/span><\/li>\n<li><span style=\"font-size: 12pt; color: #339966;\"><a style=\"color: #339966;\" href=\"https:\/\/www.breastcancertrials.org\/bct_nation\/mts\/mtsResult.seam?zip=94107&amp;gender=na&amp;searchTerm1=trop2&amp;radiusMiles=-1\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\">Trop2 Trials<\/span><\/a><\/span><\/li>\n<li><span style=\"font-size: 12pt; color: #339966;\"><a style=\"color: #339966;\" href=\"https:\/\/www.breastcancertrials.org\/bct_nation\/mts\/mtsResult.seam?zip=94107&amp;gender=na&amp;searchTerm1=androgen&amp;radiusMiles=-1\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\">Androgen Receptor Trials<\/span><\/a><\/span><\/li>\n<li><span style=\"font-size: 12pt; color: #339966;\"><a style=\"color: #339966;\" href=\"https:\/\/www.breastcancertrials.org\/bct_nation\/mts\/mtsResult.seam?zip=94107&amp;gender=na&amp;searchTerm1=akt&amp;radiusMiles=-1\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\">AKT Trials<\/span><\/a><\/span><\/li>\n<li><span style=\"font-size: 12pt; color: #339966;\"><span style=\"font-weight: 400; color: #333333;\">Solid Tumor Trials:<\/span><a style=\"color: #339966;\" href=\"https:\/\/www.breastcancertrials.org\/bct_nation\/mts\/mtsSolidTumorTrials.seam\" target=\"_blank\" rel=\"noopener\"> <span style=\"font-weight: 400;\">May Include Triple-Negative MBC<\/span><\/a><\/span><\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>Click to learn about biomarkers and targeted therapies for triple-negative MBC.<\/p>\n","protected":false},"author":1,"featured_media":5832,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_genesis_block_theme_hide_title":false,"footnotes":""},"categories":[8],"tags":[45,73,83,84],"class_list":{"0":"post-5829","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","6":"hentry","7":"category-research-news","8":"tag-immunotherapy","9":"tag-research-news","10":"tag-targeted-therapy","11":"tag-tnbc","13":"with-featured-image"},"featured_image_src":"https:\/\/breastcancertrialtalk.org\/wp-content\/uploads\/2022\/04\/AdobeStock_124042018-scaled-1-600x400.jpeg","featured_image_src_square":"https:\/\/breastcancertrialtalk.org\/wp-content\/uploads\/2022\/04\/AdobeStock_124042018-scaled-1-600x600.jpeg","author_info":{"display_name":"bctt","author_link":"https:\/\/breastcancertrialtalk.org\/?author=1"},"_links":{"self":[{"href":"https:\/\/breastcancertrialtalk.org\/index.php?rest_route=\/wp\/v2\/posts\/5829","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/breastcancertrialtalk.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/breastcancertrialtalk.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/breastcancertrialtalk.org\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/breastcancertrialtalk.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=5829"}],"version-history":[{"count":0,"href":"https:\/\/breastcancertrialtalk.org\/index.php?rest_route=\/wp\/v2\/posts\/5829\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/breastcancertrialtalk.org\/index.php?rest_route=\/wp\/v2\/media\/5832"}],"wp:attachment":[{"href":"https:\/\/breastcancertrialtalk.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=5829"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/breastcancertrialtalk.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=5829"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/breastcancertrialtalk.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=5829"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}